Growth Stocks: One to Watch (If You Can Handle the Risk)

Anyway, here’s one you might want to consider – CRISPR Therapeutics (CRSP). The market cap is $6.2 billion, which, in the world of biotech, isn’t exactly “huge,” but it’s certainly enough to stir up some interest. Here’s the kicker: they’ve got a product that’s already approved. So while it’s not making any big money yet, there’s room for that – or at least, that’s what they want you to think.





